Objective: To study the protective effect of Sijunzi Decoction on intestinal mucosal barrier injury in rats with chronic obstructive pulmonary disease (COPD) and to explore its mechanism. Methods: Totally 30 Wistar rats were randomly divided into 3 groups: blank control group, COPD model group, Sijunzi Decoction group, with 10 rats in each group. The COPD rat model was established by cigarette smoking combined with intratracheal instillation of lipopolysaccharide (LPS). Hematoxylin-eosin staining (HE) was used to observe the pathological changes of lung tissue to determine whether the model was successful. After the end of modeling, the Sijunzi Decoction group was given Sijunzi Decoction for 30 days, and the rats were sacrificed. The contents of tumor necrosis factor (TNF-α), interleukin (IL-1β) and mucin 2 (MUC2) in colon tissue were determined by enzyme-linked immunosorbent assay (ELISA), and the ultrastructure of colonic mucosal epithelium was observed by transmission electron microscopy. Results: Under the transmission electron microscope, the damage of colonic mucosal epithelial cells, the blurring of intercellular connection structure and the widening of intercellular space in the COPD model group were observed. After treatment with Sijunzi Decoction, the above structures were improved. Compared with the blank control group, the content of TNF-α and IL-1β in the colon tissue of the COPD model group increased, and the content of MUC2 decreased (P＜0.001). Compared with the COPD model group, the content of TNF-α and IL-1β in the Sijunzi Decoction group decreased, and the content of MUC2 increased (P＜0.001). Conclusion: COPD rats have intestinal mucosal barrier structure damage, which may be related to the enhancement of intestinal inflammatory response; Sijunzi Decoction can improve the intestinal mucosal barrier injury in COPD rats, and its mechanism may be related to reducing the release of inflammatory factors TNF-α and IL-1β and increasing the content of MUC2.
HAN Caiting
,
WU Kun
,
LI Min
,
FAN Hongchao
,
SONG Wu′ni′er
,
DING Ruifeng
. Effects of Sijunzi Decoction on intestinal mucosal barrier and inflammatory factors in COPD rats[J]. Journal of Baotou Medical College, 2025
, 41(1)
: 54
-59
.
DOI: 10.16833/j.cnki.jbmc.2025.01.010
[1] Jarhyan P, Hutchinson A, Khaw D, et al. Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries:a systematic review and meta-analysis[J]. Bull World Health Organ, 2022, 100(3): 216-230.
[2] 罗晨阳, 何志义. 慢性阻塞性肺疾病与合并症[J]. 结核与肺部疾病杂志, 2023, 4(5): 407-412.
[3] Kirschner SK, Deutz NEP, Jonker R, et al. Intestinal function is impaired in patients with chronic obstructive pulmonary disease[J]. Clin Nutr, 2021, 40(4): 2270-2277.
[4] 周甜, 周洵. 慢性阻塞性肺疾病合并肠道功能障碍研究进展[J]. 贵州中医药大学学报, 2022, 44(3): 85-90.
[5] Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1): 55-63.
[6] 曹慧君. 四君子汤的药理作用[J]. 当代医药论丛, 2021, 19(1): 138-141.
[7] 吕苑. 四君子汤的药理研究和临床应用[J]. 中医研究, 2012, 25(1): 76-79.
[8] 李四维, 张玲, 李春雷, 等. 熏香烟加气管注入脂多糖和结合臭氧暴露法建立大鼠慢性阻塞性肺病模型[J]. 北京中医药大学学报, 2014, 37(5): 321-324.
[9] 郑小伟. 中国实验动物模型方法学[M]. 上海: 上海中医药大学出版社, 1992: 63.
[10] 赵效国编著. 新编医学动物实验设计与方法[M]. 北京: 科学出版社, 2009, 8.
[11] Hurst JR, Siddiqui MK, Singh B, et al. A systematic literature review of the humanistic burden of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1303-1314.
[12] 郑烯, 胡雪峰. 慢性阻塞性肺疾病发病机制的研究进展[J]. 中国细胞生物学学报, 2019, 41(2): 304-311.
[13] Ojha UC, Singh DP, Choudhari OK, et al. Correlation of severity of functionalgastrointestinal disease symptoms with that of asthma and chronic obstructive pulmonary disease: a multicenter study[J]. Int J Appl Basic Med Res, 2018, 8(2): 83-88.
[14] 李长清, 李绍敏. 中医“肺病治肠”法在慢性阻塞性肺疾病治疗中的运用进展[J]. 中医药临床杂志, 2021, 33(6): 1200-1204.
[15] 张金卫, 林汉杰, 韩凌. 肠上皮细胞紧密连接的研究进展[J]. 中国医药导报, 2015, 12(6): 160-163.
[16] 聂烁, 闻正顺. 肠道黏蛋白2的分泌、结构、合成调控及其在肠道疾病发生发展中的作用[J]. 动物营养学报, 2020, 32(6): 2521-2532.
[17] An G, Wei B, Xia B, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans[J]. J Exp Med, 2007, 204: 1417-1429
[18] Bao Y, Guo Y, Li Z, et al. MicroRNA profiling in Muc2 knockout mice of colitis-associated cancer model reveals epigenetic alterations during chronic colitis malignant transformation[J]. PLoS One, 2014, 9(6): e99132.
[19] Rutten EPA, Lenaerts K, Buurman WA, et al. Disturbed intestinal integrity in patients with COPD: effects of activities of daily living[J]. Chest, 2014, 145(2): 245-252.
[20] Zhou QQ, Verne GN. Intestinal hyperpermeability:a gateway to multi-organ failure[J]. J Clin Investig, 2018, 128(11): 4764-4766.
[21] 邹孟龙, 宁芯, 陈雅璐, 等. 四君子汤介导肠道黏膜屏障防治溃疡性结肠炎的研究进展[J]. 中医药导报, 2020, 26(10): 134-137.
[22] 黄晓燕, 张涛, 王囡囡, 等. 端粒缩短介导肠上皮细胞凋亡参与溃疡性结肠炎以及四君子汤干预研究[J]. 时珍国医国药, 2014, 25(9): 2303-2305.
[23] Geltser BI, Kurpatov IG, Kotelnikov VN, et al. Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity[J]. Ter Arkh, 2018, 90(3): 81-88.
[24] 张文杰, 戴岳. “肺-肠轴”的研究进展[J]. 药学研究, 2022, 41(1): 53-56.
[25] 孔静, 王猛, 张玉华, 等.肠黏膜机械屏障的中西医结合研究进展[J].中国中西医结合外科杂志, 2020, 26:1001-1004.
[26] Olesen CM, Coskun M, Peyrin-Biroulet L, et al. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases[J]. Pharmacol Ther, 2016, 159: 110-119.
[27] Wang YX, Wang YN, Shen WL, et al. Grape seed polyphenols ameliorated dextran sulfate sodium-induced colitis via suppression of inflammation and apoptosis[J]. Pharmacology, 2020, 105(1/2): 9-18.
